Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions
Isabel Lam,Alain Ndayisaba,Amanda J Lewis,YuHong Fu,Giselle T Sagredo,Anastasia Kuzkina,Ludovica Zaccagnini,Meral Celikag,Jackson Sandoe,Ricardo L Sanz,Aazam Vahdatshoar,Timothy D Martin,Nader Morshed,Toru Ichihashi,Arati Tripathi,Nagendran Ramalingam,Charlotte Oettgen-Suazo,Theresa Bartels,Manel Boussouf,Max Schäbinger,Erinc Hallacli,Xin Jiang,Amrita Verma,Challana Tea,Zichen Wang,Hiroyuki Hakozaki,Xiao Yu,Kelly Hyles,Chansaem Park,Xinyuan Wang,Thorold W Theunissen,Haoyi Wang,Rudolf Jaenisch,Susan Lindquist,Beth Stevens,Nadia Stefanova,Gregor Wenning,Wilma D J van de Berg,Kelvin C Luk,Rosario Sanchez-Pernaute,Juan Carlos Gómez-Esteban,Daniel Felsky,Yasujiro Kiyota,Nidhi Sahni,S Stephen Yi,Chee Yeun Chung,Henning Stahlberg,Isidro Ferrer,Johannes Schöneberg,Stephen J Elledge,Ulf Dettmer,Glenda M Halliday,Tim Bartels,Vikram Khurana
DOI: https://doi.org/10.1016/j.neuron.2024.06.002
IF: 16.2
2024-07-23
Neuron
Abstract:The heterogeneity of protein-rich inclusions and its significance in neurodegeneration is poorly understood. Standard patient-derived iPSC models develop inclusions neither reproducibly nor in a reasonable time frame. Here, we developed screenable iPSC "inclusionopathy" models utilizing piggyBac or targeted transgenes to rapidly induce CNS cells that express aggregation-prone proteins at brain-like levels. Inclusions and their effects on cell survival were trackable at single-inclusion resolution. Exemplar cortical neuron α-synuclein inclusionopathy models were engineered through transgenic expression of α-synuclein mutant forms or exogenous seeding with fibrils. We identified multiple inclusion classes, including neuroprotective p62-positive inclusions versus dynamic and neurotoxic lipid-rich inclusions, both identified in patient brains. Fusion events between these inclusion subtypes altered neuronal survival. Proteome-scale α-synuclein genetic- and physical-interaction screens pinpointed candidate RNA-processing and actin-cytoskeleton-modulator proteins like RhoA whose sequestration into inclusions could enhance toxicity. These tractable CNS models should prove useful in functional genomic analysis and drug development for proteinopathies.